Abstract:The development of single compound targeting dual/multiple proteins is an efficient approach to avoid the combined drug administration. Herein, based on the modification of the previously reported lead compound A, we synthesized a new series of dihydropyranopyrazolone 7a-g and dihydro-pyrazolopyranopyrimidin-5-amine 8. The compounds were evaluated for their inhibitory in vitro enzymatic potential against α-amylase, α-glucosidase, acetylcholinesterase & proteinase. Also, the in vitro antioxidant evaluation and cytotoxicity assays were performed for all the final compounds. Interestingly, compound 8 possessed moderate activity against α-amylase (25.38 %) and α-glucosidase (29.37 %) compared to acarbose (75.43 % and 52.79 %, respectively). On the other hand, compound 7f showed a moderate anti-cholinesterase activity (46 ± 0.03 % inhibition) compared to donepezil used as a reference standard drug (67.28 ± 0.61 %). Compound 7d exhibited a moderate anti-arthritic activity (proteinase denaturation (42.21 ± 0.04 %), inhibition of proteinase (38.09 ± 0.04 %)) compared to diclofenac sodium used as a reference (47.93 ± 0.01, 44.96 ± 0.02, respectively). Compound 8 exhibited significant antioxidant activity in TAC assay and increased ABTS scavenging activity. Compounds 7 and derivative 8 exhibited reduced or no toxicity against the normal skin fibroblast thus confirming their safety at least in vitro . The in silico ADMET (absorption, distribution, metabolism, elimination and toxicity) profile of all final compounds implied their acceptability as oral bioavailable drug-likeness property. The anti-hyperglycemic activity was emphasized by the molecular docking of compound 8 showing good interactions in the acarbose binding site of both α-amylase and α-glucosidase enzymes. This study presents the dihydropyrazolopyranopyrimidin-5-amine derivative (compound 8 ) as a promising scaffold for future modification to design and develop derivatives with increased inhibitory effect against α-amylase and α-glucosidase for the management of type 2 diabetes mellitus (T2DM).

Enantiospecific synthesis of pseudoacarviosin as a potential antidiabetic agent.

Syntheses of Novel Acarviosin Analogs with Anhydro or Unsaturated Sugar Moieties

Facile, Efficient, and Enantiospecific Syntheses of 1,1 '-N-linked Pseudodisaccharides As A New Class of Glycosidase Inhibitors

Acarbose Glycosylation by AcbE for the Production of Acarstatins with Enhanced Α-Amylase Inhibitory Activity

Design and synthesis of epigallocatechin (EGC) analogs selective to inhibit α-amylase over α-glucosidases via the incorporation of caffeine acid and its derivatives

Design, Synthesis and Biological Evaluation of Novel (E)-2-benzylidene-n-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)hydrazine-1-carboxamide Derivatives As Α-Glucosidase Inhibitors.

Identification of 1,3,4-oxadiazolyl-containing β-carboline derivatives as novel α-glucosidase inhibitors with antidiabetic activity

Synthesis and biological evaluation of novel ursolic acid analogues as potential α-glucosidase inhibitors

Design, synthesis and inhibition evaluation of novel chalcone amide α-glucosidase inhibitors

[Synthesis, Biological Activity and Molecular Docking Research of N-{[(4-oxo-thiochroman-3-yl)phenyl]-methyl}acetamide Derivatives As Α-Glucosidase Inhibitors].

A New Series of Salicylic Acid Derivatives As Non-saccharide Α-Glucosidase Inhibitors and Antioxidants.

Synthesis of New Glucose-containing 5-Arylisoxazoles and their Enzyme Inhibitory Activity

Novel carbazole-oxadiazole derivatives as anti-α-glucosidase and anti-α-amylase agents: Design, synthesis, molecular docking, and biological evaluation

Piceid dicarboxylic acid esters as potent α-glucosidase inhibitors and antiglycation agents: Synthesis, spectroscopic and molecular docking studies

Synthesis of 4-thiosubstituted flavan derivatives and their hypoglycemic activities

C‐Aryl Glycosylation via Interrupted Pummerer Rearrangement

C–H Glycosylation of Native Carboxylic Acids: Discovery of Antidiabetic SGLT-2 Inhibitors

Structure-based Design of Human Pancreatic Amylase Inhibitors from the Natural Anthocyanin Database for Type 2 Diabetes.

Solvent-free synthesis, biological evaluation and in silico studies of novel 2-amino-7-(bis(2-hydroxyethyl)amino)-4H-chromene-3-carbonitrile derivatives as potential a-amylase inhibitors

Synthesis and biological ( in vitro and in silico ) screening of the 4-aryl-fused pyranopyrazole derivatives as enzyme (α-amylase, α-glucosidase, acetylcholinesterase & proteinase) inhibitors with anti-oxidant and cytotoxic activities

Synthesis and Evaluation of the Α-Glucosidase Inhibitory Activity of 3-[4-(phenylsulfonamido)benzoyl]-2h-1-benzopyran-2-one Derivatives